Portfolio Category: Medical Devices-Digital Health

Senseera’s technology ushers a new generation of liquid biopsy blood tests providing unparalleled information about disease processes in the patient’s internal organs and immune system with a single blood test. Senseera’s mission is to transform disease diagnosis and treatment and to enhance development of new therapeutics.

Established in 2016, Salignostics has developed a novel technology which utilizes saliva for lateral flow immunoassay applications. Our vision is to transform the next generation of in-vitro diagnostics by developing easy, clean, safe, low-cost, accessible and reliable saliva-based products.

OrCam’s mission is to harness the power of artificial vision by incorporating pioneering technology into a wearable platform which improves the lives of individuals who are blind, visually impaired, and have reading difficulties. The original OrCam MyEye device was launched in 2015, and the next generation OrCam MyEye 2.0 was launched in 2017.

NewStem provides new groundwork for numerous biomedical applications in advanced cancer research. With the combined advantages of haploid genetics and pluripotency, Haploid human ESCs now pave the way for numerous new biomedical applications. Our HhESCs exhibited typical pluripotent stem cell characteristics, such as self-renewal capacity and a pluripotency specific molecular signature, meaning they are able to differentiate into many other cell types, including nerve, heart, and pancreatic cells, while retaining a single set of chromosomes.

Our breakthrough technology combines the skills and expertise of the human user, cutting edge neuro-technology and state of the art machine-learning and signal processing algorithms.

HighRAD’s products are designed around its novel Region of Difference (ROD) generic platform and methodology for automatic, robust, and accurate lesion changes analysis in longitudinal volumetric scans, including CT and MRI scans.

Guide In Medical is a medical device company specializing in the respiratory field. Established in 2015 in Nazareth, Israel, the company has developed a novel groundbreaking non-invasive guided intubation device. Our device enables clear identification of the trachea, as well as fast, accurate and safe intubations even in the most difficult clinical scenarios in which visualization of the trachea is very limited.

BacoCure is developing a novel bacterial product for local therapy (intravesicular) of patients with non-muscle invasive bladder cancer. BacoCure’s lead product is a novel mutated and inactivated uropathogenic bacteria that has demonstrated impressive anti-tumor effects via a novel and differentiated mechanism of action with a better safety profile compared to Bacillus Calmette-Guerin. The product is at an advanced preclinical development stage.

LipoCure’s founder, Professor Barenholz, the co-developer of Doxil®, has been investigating liposomal drug delivery systems for several decades. LipoCure’s unique platform technology is the result of many years of his intensive research efforts to bring the myriad sufferers more effective and safer therapies.

LipoCure’s proprietary platform implements a highly-efficient innovative approach which allows for the remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. Thus, this unique technology allows for an enhanced permeability and retention (EPR) effect, a significantly improved therapeutic effect and reduced side effects of several well-established drugs widely used for the treatment of rheumatoid arthritis, multiple sclerosis and cancer.

MacroBea is the developer of a platform technology for the dermal delivery of active ingredients. The technology is based on the use of novel, tailored-made biodegradable nanocarriers to fit versatile and unmet needs, an invention developed by Prof. Simon Benita from the Institute for Drug Research at the Hebrew University in Jerusalem.